https://compound78cinhibitor.c....om/direction-metropo
At 5-year follow-up, 8 of 9 (89%) clients with MPR had been alive and disease-free. There were no cancer-related deaths among clients with MPR. In contrast, 6/11 clients without MPR experienced tumor relapse, and 3 passed away. Five-year clinical results for neoadjuvant nivolumab in resectable NSCLC compare favorably with historical results. MPR and PD-L1 positivity trended toward improved RFS, though definitive conclusions are limited by cohort size.Five-year medical effects for neoadjuvant nivolu
Like
Comment
Share
